Breast cancer

October 2, 2020

Trial Results: For women with breast cancer in the TAILORx trial, cognitive decline from chemo was early and abrupt but did not get worse over time. Cognition also declined in the group on hormone therapy alone.

Cognitive loss—or ‘brain fog’—involves memory problems, a lack of mental clarity, and difficulty keeping one’s focus. Cancer-related brain fog is common during treatment. This study dispels the idea that it is only from chemotherapy.
June 7, 2020

Now Enrolling: The CompassHER2 pCR trial is determining if certain patients with early-stage HER2 positive breast cancer may benefit from reduced chemotherapy

The purpose of this study is to find out if some patients with early-stage HER2 positive breast cancer can safely be treated with less chemotherapy than is generally used.
October 14, 2019

Lynne Alston: Why I’m grateful for researchers

Lynne Alston is a thought leader, entrepreneur, international best-selling author of A Hug Saved My Life™, cancer survivor and advocate, community ambassador, life and wellness coach, and the founder/chief executive officer of the HUGS Around America™ Foundation.